Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002453 (amenorrhea)
 6,245 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 1986-87, a qualitative research project was done in Thailand, Egypt, Indonesia, and the Dominican Republic to expand knowledge of the acceptability of NORPLANT contraceptive implants beyond continuation rates. In each of the 4 studies, in-depth interviews or focus group discussions were held with current NORPLANT users, potential acceptors, discontinuers, husband of women in the 3 groups, and service providers. The 4 countries were chosen because of their diverse cultures and religions. Most participants favored family planning. Many had used other contraceptives. Men and women in all countries were worried that oral female contraceptive agents (the pill) caused cancer. There were many objections to the IUD. In all countries but Thailand, there was little knowledge of NORPLANT. In the Dominican Republic, NORPLANT was used mostly as a child spacing method. In Indonesia, it was used for child spacing and termination of childbearing. Perceived advantages were alike in all countries. Pain during insertion and removal was a big concern of potential users. Men and women in all countries said that religion and traditional beliefs did not influence their family planning decisions. But many said that religion influenced their tolerance of side effects. In Egypt and Indonesia sterilization is unpopular because it is seen as violating Islamic law. Irregular bleeding was the major side effect and the main reason for discontinuation. Many satisfied users felt that the advantaged outweighed the side effects. Primary reasons for removal in all countries were irregular bleeding, amenorrhea, and the desire to give birth. The need for information was mentioned in all countries. In Egypt, Indonesia, and Thailand services providers reported the need for more thorough training in insertion and removal as well as continuing education sessions.
 ...
PMID:Assessing the acceptability of NORPLANT implants in four countries: findings from focus group research. 211 94

A census was done in Saradidi, Kenya from 1980 to 1982 as part of a community-based health development programme. The population was 42,755 (excluding 39 persons of unknown age or sex); 17.1% were less than five years old, 46.9% were below age 15, 4.7% were age 65 years or older and 19.7% were women in the reproductive years (age 15 to 44 years). The sex ratio was 86 males per 100 females due principally to migration of adult males for work. The mean number of persons per household was 4.0 and the mean village population was 764. The singulate mean age of marriage for men was 27.0 years and for women 19.9 years; 0.8% of adult men had never married. Only 0.1% of women by age 50 had never been married. Men were significantly more likely than women to be married to more than one spouse, divorce and separation was higher among men, and by age 50 about one-third of women were widows. Men had more years of formal education than women and young people of both sexes more than older people; 73.1% of men and 96.1% of women 60 years and more had never attended school. Infant mortality rates estimated indirectly ranged between 139 and 155 by area. A strong association was found between increasing education of the mother and decreased reported mortality of children. The total fertility of 6.2 was high but lower than the national average possibly because of the high rates of polygamy and primary infertility and the long periods of amenorrhoea and breast feeding which occurred after delivery. This area continues to have one of the highest levels of infant and child mortality in Kenya as well as relatively high fertility and a population with a very young age structure. This implies a continued very rapid rate of population growth which will make more difficult in the future the problems of delivering effective health services and overcoming poverty. A vigorous programme directed toward improving health is indicated which must include family planning.
 ...
PMID:The Saradidi, Kenya, rural health development programme: retrospective demographic analysis. 368 35

Prolactin is a polypeptide hormone essential for lactation. Its production in the lactotroph cells of the anterior pituitary is regulated primarily by the inhibitory action of hypothalamic dopamine. Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis, occurring mostly in women and presenting most commonly with amenorrhea and galactorrhea. Causes of hyperprolactinemia include physiologic, pharmacologic and pathologic factors; pituitary adenoma is a common pathologic cause. Women may present with decreased libido, infertility, oligomenorrhea/amenorrhea and galactorrhea. Men may present with decreased libido, infertility, gynecomastia or impotence. In the absence of an identifiable and treatable underlying cause, hyperprolactinemia is generally treated with dopamine agonist medications.
 ...
PMID:Clinical presentation of hyperprolactinemia. 1064 15

This chart provides guidance in choosing suitable contraceptive methods for breast-feeding mothers, non-breast-feeding mothers, women who had an abortion during the first or second trimester, and men. Men may use vasectomy at any time during the reproductive period and immediately after pregnancy. Breast-feeding mothers may use, immediately after delivery, the lactational amenorrhea method (LAM), condoms, spermicides, and sterilization. IUDs may be inserted within 48 hours or after 6 weeks for breast-feeding mothers, non-breast-feeding mothers, and postabortion women in any trimester. Risk of expulsion within 48 hours is lower with immediate insertion. After 6 weeks, breast-feeding mothers may use a diaphragm, cervical cap, sponge, or progestin-only methods such as Norplant. After 6 months, breast-feeding mothers may use any combined hormonal contraceptive. Injectables or pills are recommended for breast-feeding mothers only if lactation is well established and other options are not available or not acceptable. Non-breast-feeding mothers may immediately use condoms, spermicides, sterilization, and progestin-only methods. After 3 weeks, non-breast-feeding mothers may use combined hormonal methods. After 6 weeks, non-breast-feeding mothers may use the diaphragm, cervical cap, or sponge. Women who had a first-trimester abortion may use any method immediately. Women who had a second-trimester abortion may immediately use condoms, spermicides, progestin-only methods, sterilization, or combined hormonal methods. After 6 weeks, postabortion women may use a diaphragm, cervical cap, or sponge.
 ...
PMID:When to begin methods after pregnancy. 1229 81

The effect of chronic oral opioids on hypothalamus-pituitary-gonadal axis in women, and on bone mineral density (BMD) in men and women is not known. The objective of this cross-sectional study was to determine the effect of long-term oral opioids on gonadal status and BMD in male and female patients with chronic non-cancer pain (CNCP). We included 26 community-dwelling CNCP patients, 12 men and 14 premenopausal women, treated with oral opioids for at least one year. We obtained Visual Analogue Scale for pain score, BMD and plasma LH and FSH in all patients; menstrual history and estradiol in women; free androgen index and total and free testosterone in men. Men were older then women (p<0.05) and had used opioids for a longer period (7.2+/-3.8 and 4.1+/-1.8 years, respectively; p<0.05), but there was no difference in opioid dose or pain score between sexes. The prevalence of hypogonadism was high in men (75%), while only 21% of the women reported oligo- or amenorrhea indicating hypogonadism (P<0.01, between sexes). Osteopenia was found in 50% of men and 21% of women (p=NS). We conclude that in CNCP patients receiving chronic opioid therapy there is a much higher prevalence of hypogonadism in men then in women. This needs to be considered clinical practice.
 ...
PMID:Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. 1852 30